Circio Holding ASA (”Circio” or ”the Company”) announced, on the 9th of June 2026, that the Company has secured NOK 300m in gross proceeds from the warrant exercise program and a related underwritten private placement. Of the 67,680,945 warrants issued in connection with the February rights issue, 25,781,827 were exercised at NOK 8.2508 per share, a subscription rate of approx. 38%, raising approx. NOK 213m from more than 400 subscribers. The remaining approx. NOK 87m was secured through the underwriting commitment announced on 26 May 2026. Together with the two financings completed earlier in 2026, total capital raised in H1-26 amounts to approx. NOK 620m (USD 65m). The proceeds will be used to accelerate and broaden circVec platform development and to advance a lead gene therapy program towards IND-filing and clinical proof of concept, with an estimated financial runway to the end of 2030.
Analyst Group’s View on the Financing
Analyst Group views the NOK 300m raise as the concluding step in a sequence of financings that has re-based the Company’s capital position over H1-26, following the NOK 68.6m rights issue in Q1-26 at NOK 1.0 per share and the NOK 250m placement in April at NOK 10.80. The warrants were exercised at NOK 8.2508 per share, set at a 20% discount to the VWAP during 8–22 May. Against this backdrop, the approx. 38% subscription rate is a notable signal, reflecting a willingness among investors to commit fresh capital to the Company at a substantially re-rated level. Participation from management and employees for approx. NOK 1.44m reinforces that the financing rests on genuine conviction in the Company’s trajectory.
In Analyst Group’s assessment, the significance of the raise lies less in extending the end-date of the runway, which the April placement had already pushed towards 2030, than in the intensity of deployment now permitted. Rather than buying time at a conserved burn rate, the financing equips Circio to invest more heavily across the coming years and to capitalize on the current data and partnering momentum while the window is favorable, consistent with the stated intent to accelerate and broaden development. Analyst Group expects investments to scale up gradually as the Company expands the scientific team, invests in infrastructure, and broadens the preclinical pipeline.
Strategically, the most notable element is the explicit ambition to advance a lead gene therapy program towards IND-filing and clinical proof of concept, a clear escalation relative to the preclinical platform-licensing posture that has framed the Company’s model to date. Thus, the IND filing marks the transition from preclinical to clinical development. In Analyst Group’s view, the strategic logic of carrying a program to this threshold lies in the de-risking it represents for a prospective partner: circVec has so far been validated at the preclinical, largely reporter-gene level, which leaves a partner to bear the translational risk, the gap between preclinical performance and clinical outcomes – which is among the most significant sources of attrition in drug development. A program that has cleared an IND and generated early clinical proof of concept removes a material part of that uncertainty, which would shift circVec from a promising platform into a more validated, clinic-ready asset with human data attached.
The commercial consequence is twofold. First, deal economics scale sharply with development stage: upfronts, milestones, and royalties for a clinical-stage asset are typically multiples of what a preclinical platform commands. Second, demonstrating that circVec functions in the clinic in one indication would de-risk the platform as a whole, since the core question for any DNA-based circRNA system is whether the preclinical expression advantage translates into the clinic at all, strengthening the Company’s hand across multiple potential agreements. Analyst Group considers this a credible use of the expanded balance sheet, while noting the higher burn rate and greater in-house development risk it implies.
With funding no longer being a limiting factor, the principal variable becomes execution against the 2026 readout schedule: in vivo CAR targeted T-cell delivery data (Q2-26), AAV-circVec wet AMD disease-model efficacy data (Q2/Q3-26), CNS PoC data from the ongoing big pharma collaboration (Q3/Q4-26), and heart disease-model efficacy data (Q4-26). Analyst Group regards the eye and heart disease-model readouts as the most consequential, as they mark the step from reporter-gene proof of concept to disease-relevant efficacy and form the basis on which a lead program would be selected and advanced towards IND-filing.
In summary, Analyst Group considers the NOK 300m financing to complete a remarkable turnaround in the Company’s capital position, bringing total H1-26 proceeds to approx. NOK 620m (USD 65m) and equipping the Company to invest more heavily across the coming years. The approx. 38% subscription rate signals investor willingness to commit fresh capital at a re-rated share price, while the intent to advance a lead program towards IND-filing marks a meaningful evolution beyond preclinical platform licensing. With funding no longer the constraint, Analyst Group regards execution against the 2026 catalyst pipeline, particularly the disease-model readouts in eye and heart, as the key determinant of value creation, balanced against the elevated burn and execution risk inherent in moving towards in-house clinical development.
